Video
Author(s):
Experts in atopic disease management review the efficacy and safety data of the JAK inhibitor class, highlighting the importance of time to treatment response and itch reduction.
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.